Faeth’s phase 2 data power oral combo forward in cancer targeted by ADC heavyweights

Faeth Therapeutics’ endometrial cancer prospect has cleared the phase 2 efficacy bar, emboldening the biotech to forge ahead with efforts to establish the oral therapy in a field dominated by injectables.